FrancophonIA/ELRC3.0 huggingface dataset:
English: Trevaclyn is normally given together with a statin (the standard medicine used to reduce cholesterol) when the effectiveness of a statin taken alone is inadequate.
Estonian: Trevaclyni manustatakse tavaliselt koos statiiniga (kolesteroolisisalduse vähendamise tavaline ravim), kui ravi üksnes statiiniga ei ole efektiivne.
English: It was first used as a medicine to modify blood fat levels in the mid-1950s, but its use has been limited because of its side effects, particularly flushing (reddening of the skin).
Estonian: Esimest korda kasutati nikotiinhapet vere rasvasisalduse muutmiseks 1950. aastate keskel, kuid aine kasutamist piiravad kõrvalnähud, eelkõige õhetus.
English: They included a total of 2,349 patients who were taking either Trevaclyn or nicotinic acid.
Estonian: Uuringutes osales kokku 2349 patsienti, kes võtsid kas Trevaclyni või nikotiinhapet.
English: What is the risk associated with Trevaclyn?
Estonian: Mis riskid Trevaclyniga kaasnevad?
English: Trevaclyn is a medicine containing two active substances: nicotinic acid (also known as niacin or vitamin B3) and laropiprant.
Estonian: Trevaclyn on ravim, mis sisaldab kahte toimeainet: nikotiinhapet (teiste nimetustega niatsiin ja vitamiin B3) ning laropipranti.
English: Two studies looked at the effectiveness of Trevaclyn in modifying blood fat levels.
Estonian: Kahes uuringus uuriti Trevaclyni efektiivsust vere rasvasisalduse mõjutamisel.
English: Trevaclyn was effective in reducing the blood levels of LDL cholesterol.
Estonian: Trevaclyn vähendas efektiivselt LDL-kolesterooli sisaldust veres.
English: The third and fourth studies looked at the effectiveness of laropiprant in reducing the flushing caused by nicotinic acid.
Estonian: Kolmandas ja neljandas uuringus vaadeldi laropiprandi efektiivsust nikotiinhappe põhjustatud õhetuse vähendamisel.
English: The second study showed that the LDL cholesterol levels were further reduced when Trevaclyn was taken with simvastatin (48% reduction), compared with Trevaclyn alone (17% reduction) or simvastatin alone (37% reduction).
Estonian: Teine uuring näitas, et LDL-kolesterooli sisaldus vähenes veelgi, kui Trevaclyni manustati koos simvastatiiniga (48% võrra), samas kui LDL-kolesterooli sisaldus vähenes Trevaclyni kui ainuravimi korral 17% võrra ja simvastatiini kui ainuravimi korral 37% võrra.
English: Trevaclyn should not be used in people who may be hypersensitive (allergic) to nicotinic acid, laropiprant or any of the other ingredients.
Estonian: Trevaclyni ei tohi kasutada patsiendid, kes võivad olla nikotiinhappe, laropiprandi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: This study also looked at the symptoms of flushing using a specially designed questionnaire.
Estonian: Selles uuringus uuriti spetsiaalsete küsimustike abil ka õhetuse sümptomeid.
English: The main measure of effectiveness was the change in the blood levels of LDL cholesterol after 12 weeks.
Estonian: Efektiivsust hinnati põhiliselt vere LDLkolesterooli sisalduse muutuse järgi pärast 12-nädalast ravi.
English: The second study compared the combination of Trevaclyn and simvastatin (a statin) with Trevaclyn alone or simvastatin alone in 1,398 patients.
Estonian: Teises uuringus võrreldi Trevaclyni ja simvastatiini (teatud statiin) kombinatsiooni toimet ainult Trevaclyni või simvastatiini toimega kokku 1398 patsiendil.
English: The two active substances in Trevaclyn, nicotinic acid and laropiprant, have different modes of action.
Estonian: Trevaclyni kahel toimeainel (nikotiinhape ja laropiprant) on eri toimemehhanismid.
English: What is Trevaclyn?
Estonian: Mis on Trevaclyn?
English: For the full list of all side effects reported with Trevaclyn, see the Package Leaflet.
Estonian: Trevaclyni kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Why has Trevaclyn been approved?
Estonian: Miks Trevaclyn heaks kiideti?
English: Adding laropiprant to nicotinic acid reduced the symptoms of flushing caused by nicotinic acid.
Estonian: Laropiprandi lisamine nikotiinhappele vähendas nikotiinhappest tingitud õhetust.
English: In the first study, LDL cholesterol levels were reduced by 19% in patients taking Trevaclyn, compared with 1% in those taking placebo.
Estonian: Esimeses uuringus vähenes LDLkolesterooli sisaldus Trevaclyni saanud patsientidel 19% võrra ja platseebot saanud patsientidel 1% võrra.
English: The nicotinic acid is released more slowly from the other layer and has its effect as a fat-modifying agent.
Estonian: Nikotiinhape vabaneb teisest kihist aeglasemalt ja mõjutab vere rasvasisaldust.
English: Trevaclyn is used on its own only in patients who cannot take statins.
Estonian: Ilma statiinita kasutatakse Trevaclyni ainult juhul, kui patsient ei saa statiine võtta.
English: Flushing due to nicotinic acid is thought to occur because of the release of a substance called ‘prostaglandin D2' (PGD2) from cells in the skin, which dilates (widens) the blood vessels in the skin.
Estonian: Arvatakse, et nikotiinhappe põhjustatud õhetuse põhjus on, et naharakkudest vabaneb aine prostaglandiin D2 (PGD2), mis laiendab nahaveresooni.
English: What benefit has Trevaclyn shown during the studies?
Estonian: Milles seisnes uuringute põhjal Trevaclyni kasulikkus?
English: Trevaclyn was studied in four main studies in patients with hypercholesterolaemia or mixed dyslipidaemia.
Estonian: Trevaclyni neljas põhiuuringus uuriti hüperkolesteroleemia või segatüüpi düslipideemiga patsiente.
English: The full EPAR for Trevaclyn can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Trevaclyni kohta leiate siit.
English: In Trevaclyn tablets, laropiprant is in one of the layers, and the other layer contains nicotinic acid.
Estonian: Trevaclyni tablettides sisaldub laropiprant ühes kihis ja nikotiinhape teises.
English: In the fourth study, flushing was seen on fewer days in patients taking Trevaclyn than in those taking nicotinic acid alone.
Estonian: Neljandas uuringus täheldati õhetust väiksemal arvul päevadel nende patsientide hulgas, kes said Trevaclyni, võrreldes patsientidega, kes said ainult nikotiinhapet.
English: Trevaclyn is used in addition to diet and exercise in patients with dyslipidaemia (abnormally high levels of fat in the blood), particularly ‘combined mixed dyslipidaemia' and ‘primary hypercholesterolaemia'.
Estonian: Trevaclyni kasutatakse düslipideemiaga (vere ebaharilikult suure rasvasisaldusega) patsientide ravis lisaks dieedile ja füüsilisele koormusele, eelkõige kombineeritud segatüüpi düslipideemia ja primaarse hüperkolesteroleemia korral.
English: The effects of Trevaclyn were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Trevaclyni toimet muude katsetega.
English: The first study compared the effectiveness of Trevaclyn with that of nicotinic acid alone or placebo (a dummy treatment) in reducing the levels of LDL cholesterol in a total of 1,613 patients.
Estonian: Esimeses uuringus võrreldi Trevaclyni efektiivsust LDL-kolesterooli sisalduse vähendamisel üksnes nikotiinhappe või platseebo (näiva ravimi) efektiivsusega kokku 1613 patsiendil.
English: How is Trevaclyn used?
Estonian: Kuidas Trevaclyni kasutatakse?
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Trevaclyn's benefits are greater than its risks for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia and in patients with primary hypercholesterolaemia.
Estonian: Inimravimite komitee jõudis otsusele, et Trevaclyni kasulikkus düslipideemia ravis (eelkõige kombineeritud segatüüpi düslipideemia ja primaarse hüperkolesteroleemia ravis) on suurem kui sellega kaasnevad riskid.
English: What is Trevaclyn used for?
Estonian: Milleks Trevaclyni kasutatakse?
English: In the first and third studies, fewer patients taking Trevaclyn reported moderate, severe or extreme flushing than patients taking nicotinic acid alone.
Estonian: Esimeses ja kolmandas uuringus täheldati tugevat või ülitugevat õhetust vähem nende patsientide hulgas, kes said Trevaclyni võrreldes patsientidega, kes said ainult nikotiinhapet.
English: How does Trevaclyn work?
Estonian: Kuidas Trevaclyn toimib?
English: How has Trevaclyn been studied?
Estonian: Kuidas Trevaclyni uuriti?
English: Flushing was measured using the flushing symptom questionnaire.
Estonian: Õhetuse mõõtmisel kasutati õhetuse küsimustikke.
English: Previously known as Arcalyst.
Estonian: Varasem nimetus Arcalyst.
English: Patients may inject themselves once they have been trained if their doctor believes it is appropriate.
Estonian: Patsiendid võivad süstida end ise, kui neid on õpetatud seda õigesti tegema ja kui arst peab seda kohaseks.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Arcalyst to Regeneron UK Limited on 23 October 2009.
Estonian: Euroopa Komisjon andis Arcalysti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Regeneron UK Limited 23. oktoobril 2009.
English: This means that because the diseases are rare, it has not been possible to obtain complete information about Rilonacept Regeneron.
Estonian: See tähendab, et kuna haigus on haruldane, ei ole olnud võimalik Rilonacept Regeneroni kohta saada täielikku teavet.
English: It must not be used in patients with an active, severe infection.
Estonian: Seda ei tohi kasutada aktiivse raske põletikuga patsiendid.
English: It contains the active substance rilonacept (80 mg/ml).
Estonian: Ravim sisaldab toimeainena rilonatsepti (80 mg/ml).
English: The starting dose is 4.4 mg per kilogram body weight (up to a maximum of 320 mg), which is followed a week later by once weekly injections of 2.2 mg/kg (up to a maximum of 160 mg).
Estonian: Algannus on 4,4 mg (kuni 320 mg) kehakaalu kilogrammi kohta, sellele järgneb ühe nädala pärast annus 2,2 mg/kg (kuni 160 mg) üks kord nädalas.
English: The name of the medicine was changed to Rilonacept Regeneron on 23 July 2010.
Estonian: Ravimi nimetus muudeti 23. juulil 2010 kujule Rilonacept Regeneron.
English: The main measure of effectiveness was how much their symptoms reduced after the six-week treatment and how much the improvements were maintained after the nine-week treatment.
Estonian: Efektiivsuse põhinäitaja oli sümptomite vähenemine pärast kuuenädalast ravi ja paranemistulemuste säilimine pärast üheksanädalast ravi.
English: The full EPAR for Rilonacept Regeneron can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Rilonacept Regeneroni kohta on ameti veebilehel: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: Adults should be given a starting dose of two injections of 160 mg each in two different parts of the body on the same day.
Estonian: Täiskasvanutel on soovitatav algannus 160 mg kahe süstina samal päeval eri kehaosadesse.
English: The CHMP decided that Rilonacept Regeneron's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Rilonacept Regeneroni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
English: Severe disabilities such as deafness and loss of vision may also occur.
Estonian: Võib tekkida ka raske puue, näiteks kurtus või nägemiskaotus.
English: This leads to inflammation in many parts of the body, with symptoms such as fever, rash, joint pain, and tiredness.
Estonian: Selle tagajärjel tekib organismis põletik, mille sümptomid on näiteks palavik, lööve, liigesevalu ja väsimus.
English: Blocking interleukin-1 may interfere with the body's immune response to infection and there have been reports of serious infections in patients taking Rilonacept Regeneron.
Estonian: Interleukiin-1 toime blokeerimine võib mõjutada organismi immuunsüsteemi vastureaktsiooni infektsioonidele ning on teatatud Rilonacept Regeneroni manustavate patsientide rasketest infektsioonidest.
English: The company that makes Rilonacept Regeneron will provide regular information on the safety and effectiveness of Rilonacept Regeneron in adults and children from a registry and will perform a study in children to further investigate what happens to the medicine in the body.
Estonian: Rilonacept Regeneroni tootja pakub korrapäraseid registriandmeid Rilonacept Regeneroni ohutuse ja efektiivsuse kohta täiskasvanute ja laste ravis ning korraldab uuringu lastel, et uurida põhjalikumalt, mis organismis ravimiga toimub.
English: Five symptoms (rash, fever or chills, joint pain, tiredness and eye redness or pain) were assessed by patients themselves on a scale from 0 to 10 points.
Estonian: Patsiendid hindasid viit sümptomit (nahalööve, palavik või külmavärinad, liigesevalu, väsimus, silmade punetus ja valu) 0-10-punktisel skaalal.
English: Patients treated with Rilonacept Regeneron must be given an alert card that summarises the key safety information about the medicine.
Estonian: Ravimit Rilonacept-Regeneroni saavatele patsientidele tuleb anda hoiatuskaart, millel on ravimi kokkuvõtlik ohutusteave.
English: Rilonacept Regeneron should not be used in people who may be hypersensitive (allergic) to rilonacept or any of the other ingredients.
Estonian: Rilonacept Regeneroni ei tohi kasutada patsiendid, kes võivad olla rilonatsepti või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Because the number of patients with CAPS is low, the diseases are considered ‘rare', and Rilonacept Regeneron was designated an ‘orphan medicine' (a medicine used in rare diseases) on 10 July 2007.
Estonian: Et CAPS-sündroomidega patsientide arv on väike ja see haigus esineb harva, nimetati Rilonacept Regeneron 10. juulil 2007 harvikravimiks.
English: The company that makes Rilonacept Regeneron will provide doctors in all Member States who will use Rilonacept Regeneron with a pack containing the prescribing information, a patient alert card and information for doctors explaining the risk of side effects and how to use the medicine properly.
Estonian: Rilonacept Regeneroni tootja edastab kõikide liikmesriikide arstidele, kes hakkavad Rilonacept Regeneroni kasutama, teabepakme, mis sisaldab teavet ravimi määramise kohta, patsiendi hoiatuskaarti ning arstidele suunatud teavet kõrvalnähtude riski ja ravimi nõuetekohase kasutamise kohta.
English: The most common side effects with Rilonacept Regeneron (seen in more than 1 patient in 10) are reactions at the injection site, upper respiratory tract infections (colds), sinusitis (inflammation of the sinuses) and headache.
Estonian: Rilonacept Regeneroni kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on süstekoha reaktsioonid, ülemiste hingamisteede nakkused (nohu), sinusiit (põskkoopapõletik) ja peavalu.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rilonacept Regeneron.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Rilonacept Regeneron, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Rilonacept Regeneroniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Rilonacept Regeneron is used to treat CAPS that are causing severe symptoms in adults and children aged 12 years and older, including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).
Estonian: Rilonacept Regeneroni kasutatakse raskekujuliste sümptomitega CAPS-sündroomide, sealhulgas familiaalse külmast tingitud autoinflammatoorse sündroomi (FCAS) ja Muckle'i-Wellsi sündroomi (MWS) raviks täiskasvanutel ja vähemalt 12-aastastel lastel.
English: In the first part of one main study involving 47 patients with CAPS, patients were given either Rilonacept Regeneron or placebo (a dummy treatment) for six weeks.
Estonian: Põhiuuringu esimeses etapis, milles osales 47 CAPS-sündroomidega patsienti, anti patsientidele kuue nädala jooksul Rilonacept Regeneroni või platseebot (näiv ravim).
English: Rilonacept Regeneron is used to treat cryopyrin-associated periodic syndromes (CAPS).
Estonian: Rilonacept Regeneroni kasutatakse krüopüriiniga seotud perioodiliste sündroomide (CAPS) raviks.
English: By attaching to interleukin-1 beta, it blocks its activity, helping to relieve the symptoms of the disease.
Estonian: Beeta-1-interleukiiniga seondumisel blokeerib rilonatsept aine toime ja aitab leevendada haiguse sümptomeid.
English: After the sixweek treatment, patients who received Rilonacept Regeneron had a reduction in symptoms of 2.5 points on the scale compared with 0.3 points in patients who received placebo.
Estonian: Pärast kuuenädalast ravi vähenesid Rilonacept Regeneroni saanud patsientidel sümptomid 2,5 skaalapunkti võrra ja platseeborühma patsientidel 0,3 skaalapunkti võrra.
English: Rilonacept Regeneron rilonacept
Estonian: Rilonacept Regeneron rilonatsept
English: This document is a summary of the European public assessment report (EPAR) for Rilonacept Regeneron.
Estonian: Käesolev dokument on ravimi Rilonacept Regeneron Euroopa avaliku hindamisaruande kokkuvõte.
English: In the second part of the study, all patients were given Rilonacept Regeneron treatment before receiving either Rilonacept Regeneron or placebo for another nine weeks.
Estonian: Põhiuuringu teises etapis said kõik patsiendid Rilonacept Regeneroni ja seejärel said nad Rilonacept Regeneroni või platseebot veel üheksa nädala jooksul.
English: In the second part of the study, symptoms increased more in patients switched to placebo (0.9 points) compared with patients who remained on Rilonacept Regeneron (0.1 points).
Estonian: Uuringu teises etapis sümptomid suurenesid 0,9 punkti võrra patsientidel, kes läksid üle platseebole, ja 0,1 punkti võrra patsientidel, kes jätkasid Rilonacept Regeneroni ravi.
English: What measures are being taken to ensure the safe use of Rilonacept Regeneron?
Estonian: Mis meetmeid võetakse, et tagada Rilonacept Regeneroni kasutamise ohutus?
English: A week later, the patient should start receiving once weekly injections of 160 mg. For children aged from 12 to 17 years, the dose will depend on the patient's weight.
Estonian: 12-17-aastaste laste annus sõltub patsiendi kaalust.
English: CAPS are a group of diseases where patients have a defect in the gene that produces a protein called cryopyrin.
Estonian: See on haiguste rühm, mille korral on patsiendil valgu krüopüriini teket reguleeriv geen defektne.
English: The summary of opinion of the Committee for Orphan Medicinal Products for Rilonacept Regeneron is available here.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Rilonacept Regeneroni kohta on siin.
English: For the full list of all side effects reported with Rilonacept Regeneron, see the package leaflet.
Estonian: Rilonacept Regeneroni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What information is still awaited for Rilonacept Regeneron?
Estonian: Mis teavet Rilonacept Regeneroni kohta veel oodatakse?
English: Rilonacept Regeneron is a powder and solvent that are made up into a solution for injection.
Estonian: Rilonacept Regeneron on pulber ja lahusti, millest valmistatakse süstelahus.
English: The active substance in Rilonacept Regeneron, rilonacept, is an interleukin inhibitor.
Estonian: Rilonacept Regeneroni toimeaine rilonatsept on interleukiiniinhibiitor.
English: It works by attaching to chemical messengers in the body called interleukin-1beta and interleukin-1 alpha. One of these messengers, interleukin-1 beta, is produced at high levels in patients with CAPS, causing inflammation.
Estonian: Rilonatsept seondub organismis närvirakkudevahelisi signaale edastavate keemiliste ainete beeta-1-interleukiini ja alfa-1-interleukiiniga.
English: Rilonacept Regeneron was more effective than placebo at treating symptoms of CAPS.
Estonian: Rilonacept Regeneron oli krüopüriiniga seotud perioodiliste sündroomide (CAPS) ravis efektiivsem kui platseebo.
English: What is Rilonacept Regeneron?
Estonian: Mis on Rilonacept Regeneron?
English: Treatment with Rilonacept Regeneron should be started and supervised by a specialist doctor experienced in diagnosing and treating CAPS.
Estonian: Ravi Rilonacept Regeneroniga tohib alustada üksnes CAPS-sündroomide diagnoosimises ja ravis kogenud eriarst ning see peab toimuma tema järelevalve all.
English: How has Rilonacept Regeneron been studied?
Estonian: Kuidas Rilonacept Regeneroni uuriti?
English: Why has Rilonacept Regeneron been approved?
Estonian: Miks Rilonacept Regeneron heaks kiideti?
English: What is the risk associated with Rilonacept Regeneron?
Estonian: Mis riskid Rilonacept Regeneroniga kaasnevad?
English: Other information about Rilonacept Regeneron:
Estonian: Muu teave Rilonacept Regeneroni kohta
English: How is Rilonacept Regeneron used?
Estonian: Kuidas Rilonacept Regeneroni kasutatakse?
English: Rilonacept Regeneron has been authorised under ‘exceptional circumstances'.
Estonian: Rilonacept Regeneroni müügiluba anti erandkorras.
English: Rilonacept Regeneron is given as injections under the skin.
Estonian: Rilonacept Regeneroni manustatakse nahaaluse süstina.
English: What is Rilonacept Regeneron used for?
Estonian: Milleks Rilonacept Regeneroni kasutatakse?
English: How does Rilonacept Regeneron work?
Estonian: Kuidas Rilonacept Regeneron toimib?
English: What benefit has Rilonacept Regeneron shown during the studies?
Estonian: Milles seisneb uuringute põhjal Rilonacept Regeneroni kasulikkus?
English: • Wash your hands carefully.
Estonian: • Peske oma käed hoolikalt puhtaks.
English: Elderly (≥65 years old)
Estonian: Eakad (≥ 65-aastased)
English: Data in patients older than 65 years are limited.
Estonian: Andmed üle 65-aastaste patsientide kohta on piiratud.
English: Before you begin
Estonian: Enne alustamist:
English: Genotoxic and carcinogenic potential is not expected.
Estonian: Genotoksiline ja kantserogeenne potentsiaal tõenäoliselt puudub.
English: All adapters supplied with the kit are identical.
Estonian: Kõik komplektiga tarnitud adapterid on identsed.
English: Other medicines and Ruconest
Estonian: Muud ravimid ja Ruconest
English: Step 14: Documenting the administration Please record (e.g. in your diary):
Estonian: 14. samm: manustamise dokumenteerimine Palun talletage (s.t oma päevikusse):
English: Do not give this medicine to children under 12 years old.
Estonian: See ravim ei ole ette nähtud kasutamiseks alla 12-aastastel lastel.
English: No formal distribution studies have been performed.
Estonian: Formaalseid jaotumise uuringuid ei ole läbi viidud.
English: Date of first authorisation: 28 October 2010 Date of latest renewal: 18 September 2015
Estonian: Müügiloa esmase väljastamise kuupäev: 28/10/2010 Müügiloa viimase uuendamise kuupäev: 18/09/2015
English: The adapter must remain in its plastic packaging.
Estonian: Adapter peab jääma oma plastist pakendi sisse.
English: Sanofi-Chimie Route d'Avignon Aramon 30390 France
Estonian: Sanofi-Chimie Route d'Avignon Aramon 3039
English: 5711 CP Someren The Netherlands
Estonian: 5711 CP Someren Holland
English: This is the end which has no needle.
Estonian: See on ots, kus ei ole nõela.
English: The medicinal product should be used immediately (see section 6.3).
Estonian: Ravim tuleb ära kasutada kohe (vt lõik 6.3).
English: Step 9: Required components
Estonian: 9. samm: vajalikud komponendid
English: Contact your doctor or nearest hospital if this occurs.
Estonian: Sel puhul võtke ühendust oma arsti või lähima haiglaga.
English: • Ensure the kit package is complete and contains all components listed in section 6 of this leaflet.
Estonian: • Veenduge, et komplekti pakend on täielik ja sisaldab kõiki selle infolehe lõigus 6 loetletud komponente.
English: Ensure that the tourniquet is released.
Estonian: Veenduge, et žgutt vabastatakse.